OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]Status:Awaiting developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC